We are proud to announce that PhenoPath is now a Quest Diagnostics Company.

JAK2 V617F pin


JAK2 V617F

Methodology: PCR

Clinical Significance:
This real time PCR test detects the exon 14 JAK2 V617F mutation, which is identified in the great majority of polycythemia vera (PV) cases as well as in other non-CML myeoloproliferative disorders. The JAK2 V617F mutation causes a constitutive activation of the JAK2 tyrosine kinase, which is believed to confer erythropoietin hypersensitivity and erythropoietin-independent survival of the myeloid stem cell. Additionally, these diseases may also transform into acute myeloid leukemia. Thus, detection of the JAK2 (V617F) mutation provides important confirmation of non-CML MPD. Type: Real-Time PCR, Qualitative

Organ: Skin & Mucosa

Disease State: Myeloproliferative Neoplasms, Including Chronic Myelogenous Leukemia (CML)

CPT Code(s): 81270; 88381 may apply. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Turnaround Time: Within 4-8 business days of receipt

Schedule: Wednesday

Specimen Requirements:
• Peripheral blood, Preferred: 5 ml in EDTA (purple top) / Acceptable: 5 ml in sodium heparin (green top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in EDTA (purple top) / Acceptable: 1-2 ml in sodium heparin (green top) - OR - • Fresh tissue in RPMI - OR - • Formalin-fixed, paraffin-embedded tissue (FFPE)